Investor_Tester
12 Feb 2016
Re: Liquid biopsy market Great findGood to see this company is actively buying loads of ventures.....wonder if they would ever dip their toes into ANGLE ???As per the competing product , they don't have CE Mark or any other patents that we have at this stage...but nonetheless , good to have competition to drive us forward
Pyatnitsky
28 Jan 2016
Liquid biopsy market Competition is intensifying in this field. I'm cross posting a comment from Imperial Innovations:Imperial Innovations Group portfolio company Inivata has completed a GBP31.5 million series A fundraising. Innovations has committed GBP10.0 million to the round alongside existing investors Cambridge Innovation Capital, and Johnson and Johnson Innovation (JJDC) who also participated in the round, as did new investor Woodford Patient Capital Trust.Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient's cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This minimally-invasive approach - a liquid biopsy - offers a revolution in how cancer is detected, monitored and treated. The test allows precise analysis of cancer-related mutations present in ctDNA, and is designed to provide oncologists with clinically actionable genomic information to guide therapy selection, monitor treatment progress and detect new mutations as they emerge. As of 31 July 2015, Innovations had invested GBP1.5 million in Inivata with a net carrying value of GBP1.5 million. Following this new investment, Innovations will have increased its investment to GBP11.5 million and the Group will hold a 30.6% interest in the Company.
Good money after bad
28 Jan 2016
Results Well that didn't tell us much other than they're burning through the cash !
millwallfan
25 Jan 2016
Re: Publication Yes seems positive - so price dips ! Think the only real shaker will be FDA approval and with so few shares in issue relatively speaking hopefully fireworks!
autpaxautbellum
24 Jan 2016
Publication AGL website showing publication of research by Hamburg which seems to be positive.
millwallfan
22 Jan 2016
Re: info And look what happened to GWP once in USA
forwardloop
21 Jan 2016
info Shares mag buy via alliance trust news emailAngle set for FDA voteApproval will open door to lucrative US marketMark Dunne Cancer-focused liquid biopsy developer Angle (AGL:AIM) is months away from a decision by the Food & Drug Administration (FDA) that could see its Parsortix device sold in the US. The £40 million cap filed the device, which identifies cancer cells in blood samples, with the US regulator six months ago. Approval would allow the device to be sold into the £8 billion a year clinical market for cancer diagnostics and is expected to prove a huge catalyst for share price gains. Confidence is high with a pilot study by the Medical University of Vienna highlighting that the device is almost 100% successful at detecting ovarian cancer, beating the 24.5% average achieved using existing methods. If the device is cleared for sale then the Guilford-based company is forecast to make a profit in 2018, but this could happen sooner if corporate deals are agreed. The system has CE mark allowing its sale in Europe for research use, a market the company believes is worth £250 million a year. Parsortix captures cancer cells that have been shed from a tumour and allows for targeted treatment of the conditions. Shares says: "Not one for widows and orphans as its fortunes turn on FDA decision but the portents look good BUY at 67.2p."
autpaxautbellum
19 Jan 2016
Re: First Commercial Sales Results 28 Jan - so not long to wait
millwallfan
19 Jan 2016
Re: First Commercial Sales This has drifted from 105 to 65 in 9 months and whilst there has been little news what there has been is relatively positive. With a fairly low number of shares in issue IMHO this is still worth holding. I seem to remember an informed poster advising that commercial sales income was based on income per 'test' as opposed to a single sale income per 'machine'. If that is correct and the accuracy and efficacy of the process really is so far ahead of the competition then, although frustrating, I will hold. An investor update from the company would be really welcomed !!
Good money after bad
15 Dec 2015
Re: First Commercial Sales Unfortunately there's no mention of the value of sales or any forecasts....until then the share price will stagnate.....
Investor_Tester
15 Dec 2015
First Commercial Sales Well that's a great milestone today , long overdue and will only increase from here.Hopefully that will provide good cash flow and avoid any further dilution in the futureNext milestone is the long awaited FDA approvals in US....then the world is our oyster! GLA and have a great festive break IT
Pyatnitsky
10 Dec 2015
Re: ? I think it's been reclassified from 'Technology' to 'Health Care'
Petet1
09 Dec 2015
? Anyone have any ideas as to what is happening here ?
millwallfan
31 Oct 2015
Re: Falling ..... No expert but probably symptom of no news update or any real progress. Seems FDA approval is key to some commentators, hopefully more knowledgeable . When I enquirer as to basis of future income a few weeks ago on this board I must admit I was very hopeful. Also the recent rights issue was massively oversubscribed which is another positive. I tried to double my holding and got 20%.. A hold for me
Petet1
30 Oct 2015
Falling ..... Down every day this week, was at the same price last October , starting to loose faith now and wondering if we will ever see a steady climb here and make a profit !
